CH618516A5 - - Google Patents

Download PDF

Info

Publication number: CH618516A5
Authority: CH; Switzerland
Prior art keywords: antibody; antigen; sample; radioactivity; detector
Prior art date: 1976-03-12

Application number

CH313277A

Other languages

English (en)

French (fr)

Inventor

Gary Brooker

Wesley Lawrence Terasaki

Michael Glendon Price

Original Assignee

Univ Virginia

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1976-03-12

Filing date

1977-03-11

Publication date

1980-07-31

1976-03-12 Priority claimed from US05/666,302 external-priority patent/US4022577A/en

1977-03-11 Application filed by Univ Virginia filed Critical Univ Virginia

1980-07-31 Publication of CH618516A5 publication Critical patent/CH618516A5/fr

Links

239000000427 antigen Substances 0.000 claims description 109
102000036639 antigens Human genes 0.000 claims description 99
108091007433 antigens Proteins 0.000 claims description 99
239000000523 sample Substances 0.000 claims description 79
239000000243 solution Substances 0.000 claims description 55
239000003463 adsorbent Substances 0.000 claims description 43
239000012488 sample solution Substances 0.000 claims description 43
238000000034 method Methods 0.000 claims description 42
238000011534 incubation Methods 0.000 claims description 40
238000005259 measurement Methods 0.000 claims description 37
239000000126 substance Substances 0.000 claims description 31
238000000926 separation method Methods 0.000 claims description 25
239000000203 mixture Substances 0.000 claims description 21
238000003127 radioimmunoassay Methods 0.000 claims description 19
230000003068 static effect Effects 0.000 claims description 16
239000007853 buffer solution Substances 0.000 claims description 14
230000000694 effects Effects 0.000 claims description 11
238000005086 pumping Methods 0.000 claims description 11
230000002285 radioactive effect Effects 0.000 claims description 10
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 8
229910052799 carbon Inorganic materials 0.000 claims description 8
230000005855 radiation Effects 0.000 claims description 8
238000006243 chemical reaction Methods 0.000 claims description 6
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims description 5
238000011049 filling Methods 0.000 claims description 5
239000003456 ion exchange resin Substances 0.000 claims description 5
229920003303 ion-exchange polymer Polymers 0.000 claims description 5
238000002955 isolation Methods 0.000 claims description 4
239000007788 liquid Substances 0.000 claims description 4
238000002156 mixing Methods 0.000 claims description 4
230000005587 bubbling Effects 0.000 claims 1
239000002699 waste material Substances 0.000 claims 1
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 44
229940125396 insulin Drugs 0.000 description 23
102000004877 Insulin Human genes 0.000 description 21
108090001061 Insulin Proteins 0.000 description 21
229960005156 digoxin Drugs 0.000 description 21
LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 20
LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 20
LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 20
102400000344 Angiotensin-1 Human genes 0.000 description 14
101800000734 Angiotensin-1 Proteins 0.000 description 14
ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 14
230000008569 process Effects 0.000 description 14
229940034208 thyroxine Drugs 0.000 description 14
XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 14
XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 13
210000002966 serum Anatomy 0.000 description 12
239000000872 buffer Substances 0.000 description 11
238000001179 sorption measurement Methods 0.000 description 11
238000003556 assay Methods 0.000 description 10
238000009739 binding Methods 0.000 description 10
229940095074 cyclic amp Drugs 0.000 description 10
229920001467 poly(styrenesulfonates) Polymers 0.000 description 10
239000002287 radioligand Substances 0.000 description 10
ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 description 9
ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 8
238000010521 absorption reaction Methods 0.000 description 8
238000004458 analytical method Methods 0.000 description 8
230000008878 coupling Effects 0.000 description 8
238000010168 coupling process Methods 0.000 description 8
238000005859 coupling reaction Methods 0.000 description 8
229920000936 Agarose Polymers 0.000 description 7
IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 7
IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 7
229940088597 hormone Drugs 0.000 description 7
239000005556 hormone Substances 0.000 description 7
238000003018 immunoassay Methods 0.000 description 7
229920005654 Sephadex Polymers 0.000 description 6
239000012507 Sephadex™ Substances 0.000 description 6
230000004913 activation Effects 0.000 description 6
239000002245 particle Substances 0.000 description 6
239000011347 resin Substances 0.000 description 6
229920005989 resin Polymers 0.000 description 6
241000283707 Capra Species 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
150000001718 carbodiimides Chemical class 0.000 description 5
150000001875 compounds Chemical class 0.000 description 5
125000004122 cyclic group Chemical group 0.000 description 5
238000010790 dilution Methods 0.000 description 5
239000012895 dilution Substances 0.000 description 5
239000003814 drug Substances 0.000 description 5
238000005342 ion exchange Methods 0.000 description 5
239000003446 ligand Substances 0.000 description 5
239000007787 solid Substances 0.000 description 5
IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
102000011923 Thyrotropin Human genes 0.000 description 4
108010061174 Thyrotropin Proteins 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000008280 blood Substances 0.000 description 4
229920002678 cellulose Polymers 0.000 description 4
239000001913 cellulose Substances 0.000 description 4
229940079593 drug Drugs 0.000 description 4
230000002706 hydrostatic effect Effects 0.000 description 4
229940027941 immunoglobulin g Drugs 0.000 description 4
230000035945 sensitivity Effects 0.000 description 4
KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 4
238000012360 testing method Methods 0.000 description 4
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
229920002307 Dextran Polymers 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
239000004793 Polystyrene Substances 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 3
238000007792 addition Methods 0.000 description 3
238000001514 detection method Methods 0.000 description 3
238000010586 diagram Methods 0.000 description 3
239000000499 gel Substances 0.000 description 3
239000011521 glass Substances 0.000 description 3
239000012535 impurity Substances 0.000 description 3
238000009434 installation Methods 0.000 description 3
238000002372 labelling Methods 0.000 description 3
239000000463 material Substances 0.000 description 3
230000002572 peristaltic effect Effects 0.000 description 3
229920002223 polystyrene Polymers 0.000 description 3
238000005070 sampling Methods 0.000 description 3
239000000725 suspension Substances 0.000 description 3
210000002700 urine Anatomy 0.000 description 3
MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 2
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 2
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
102220600408 Alpha-lactalbumin_I12S_mutation Human genes 0.000 description 2
102000011022 Chorionic Gonadotropin Human genes 0.000 description 2
108010062540 Chorionic Gonadotropin Proteins 0.000 description 2
101800000414 Corticotropin Proteins 0.000 description 2
SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 2
DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 2
108060003199 Glucagon Proteins 0.000 description 2
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
102000003886 Glycoproteins Human genes 0.000 description 2
108090000288 Glycoproteins Proteins 0.000 description 2
239000000637 Melanocyte-Stimulating Hormone Substances 0.000 description 2
108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
102000003982 Parathyroid hormone Human genes 0.000 description 2
108090000445 Parathyroid hormone Proteins 0.000 description 2
241001494479 Pecora Species 0.000 description 2
102000004576 Placental Lactogen Human genes 0.000 description 2
108010003044 Placental Lactogen Proteins 0.000 description 2
239000000381 Placental Lactogen Substances 0.000 description 2
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
230000021736 acetylation Effects 0.000 description 2
238000006640 acetylation reaction Methods 0.000 description 2
229960002478 aldosterone Drugs 0.000 description 2
239000003957 anion exchange resin Substances 0.000 description 2
230000009830 antibody antigen interaction Effects 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
239000003610 charcoal Substances 0.000 description 2
229920001429 chelating resin Polymers 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
230000000052 comparative effect Effects 0.000 description 2
238000011109 contamination Methods 0.000 description 2
206010012601 diabetes mellitus Diseases 0.000 description 2
238000009792 diffusion process Methods 0.000 description 2
QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 2
SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 2
239000012530 fluid Substances 0.000 description 2
OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
229940084986 human chorionic gonadotropin Drugs 0.000 description 2
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
229960000890 hydrocortisone Drugs 0.000 description 2
230000003053 immunization Effects 0.000 description 2
238000002649 immunization Methods 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
239000012528 membrane Substances 0.000 description 2
239000002808 molecular sieve Substances 0.000 description 2
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
229960005181 morphine Drugs 0.000 description 2
239000000199 parathyroid hormone Substances 0.000 description 2
229960001319 parathyroid hormone Drugs 0.000 description 2
KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 2
229920002401 polyacrylamide Polymers 0.000 description 2
229920000058 polyacrylate Polymers 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
238000012545 processing Methods 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
239000000376 reactant Substances 0.000 description 2
229960002101 secretin Drugs 0.000 description 2
239000001632 sodium acetate Substances 0.000 description 2
235000017281 sodium acetate Nutrition 0.000 description 2
URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
239000007790 solid phase Substances 0.000 description 2
239000012086 standard solution Substances 0.000 description 2
229960002317 succinimide Drugs 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
229940035722 triiodothyronine Drugs 0.000 description 2
229960003726 vasopressin Drugs 0.000 description 2
239000011534 wash buffer Substances 0.000 description 2
-1 "Dowex 1" Chemical class 0.000 description 1
DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 description 1
CHRJZRDFSQHIFI-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;styrene Chemical compound C=CC1=CC=CC=C1.C=CC1=CC=CC=C1C=C CHRJZRDFSQHIFI-UHFFFAOYSA-N 0.000 description 1
NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
HWDMHJDYMFRXOX-XVFCMESISA-N 2',3'-cyclic UMP Chemical compound N1([C@@H]2O[C@@H]([C@H]3OP(O)(=O)O[C@H]32)CO)C=CC(=O)NC1=O HWDMHJDYMFRXOX-XVFCMESISA-N 0.000 description 1
PKAUICCNAWQPAU-UHFFFAOYSA-N 2-(4-chloro-2-methylphenoxy)acetic acid;n-methylmethanamine Chemical compound CNC.CC1=CC(Cl)=CC=C1OCC(O)=O PKAUICCNAWQPAU-UHFFFAOYSA-N 0.000 description 1
BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
DMJWGQPYNRPLGA-KQYNXXCUSA-N 3',5'-cyclic IMP Chemical compound C1=NC2=C(O)N=CN=C2N1[C@@H]1O[C@@H]2COP(O)(=O)O[C@H]2[C@H]1O DMJWGQPYNRPLGA-KQYNXXCUSA-N 0.000 description 1
239000000275 Adrenocorticotropic Hormone Substances 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
108010064733 Angiotensins Proteins 0.000 description 1
102000015427 Angiotensins Human genes 0.000 description 1
101000767534 Arabidopsis thaliana Chorismate mutase 2 Proteins 0.000 description 1
206010003445 Ascites Diseases 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
HWDMHJDYMFRXOX-UHFFFAOYSA-N CUMP Natural products C12OP(O)(=O)OC2C(CO)OC1N1C=CC(=O)NC1=O HWDMHJDYMFRXOX-UHFFFAOYSA-N 0.000 description 1
206010007559 Cardiac failure congestive Diseases 0.000 description 1
102400000739 Corticotropin Human genes 0.000 description 1
GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
WDJUZGPOPHTGOT-OAXVISGBSA-N Digitoxin Natural products O([C@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C[C@H]1O)[C@H]1O[C@@H](C)[C@H](O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1 WDJUZGPOPHTGOT-OAXVISGBSA-N 0.000 description 1
206010013457 Dissociation Diseases 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
229930091371 Fructose Natural products 0.000 description 1
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
239000005715 Fructose Substances 0.000 description 1
102400000921 Gastrin Human genes 0.000 description 1
108010052343 Gastrins Proteins 0.000 description 1
102000051325 Glucagon Human genes 0.000 description 1
108010088406 Glucagon-Like Peptides Proteins 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical class ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
101000986989 Naja kaouthia Acidic phospholipase A2 CM-II Proteins 0.000 description 1
108010018674 Neurophysins Proteins 0.000 description 1
102000002710 Neurophysins Human genes 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
102400000050 Oxytocin Human genes 0.000 description 1
101800000989 Oxytocin Proteins 0.000 description 1
XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
102100027467 Pro-opiomelanocortin Human genes 0.000 description 1
102000003946 Prolactin Human genes 0.000 description 1
108010057464 Prolactin Proteins 0.000 description 1
102100028255 Renin Human genes 0.000 description 1
108090000783 Renin Proteins 0.000 description 1
108010086019 Secretin Proteins 0.000 description 1
102100037505 Secretin Human genes 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
239000004809 Teflon Substances 0.000 description 1
229920006362 Teflon® Polymers 0.000 description 1
AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
102000002248 Thyroxine-Binding Globulin Human genes 0.000 description 1
108010000259 Thyroxine-Binding Globulin Proteins 0.000 description 1
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
108010004977 Vasopressins Proteins 0.000 description 1
102000002852 Vasopressins Human genes 0.000 description 1
241000700605 Viruses Species 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000009471 action Effects 0.000 description 1
230000001464 adherent effect Effects 0.000 description 1
WYTGDNHDOZPMIW-RCBQFDQVSA-N alstonine Natural products C1=CC2=C3C=CC=CC3=NC2=C2N1C[C@H]1[C@H](C)OC=C(C(=O)OC)[C@H]1C2 WYTGDNHDOZPMIW-RCBQFDQVSA-N 0.000 description 1
PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
239000001166 ammonium sulphate Substances 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
229960003473 androstanolone Drugs 0.000 description 1
239000002416 angiotensin derivative Substances 0.000 description 1
238000005349 anion exchange Methods 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
229960002319 barbital Drugs 0.000 description 1
239000011324 bead Substances 0.000 description 1
230000008901 benefit Effects 0.000 description 1
108010042362 beta-Lipotropin Proteins 0.000 description 1
239000012888 bovine serum Substances 0.000 description 1
DMJWGQPYNRPLGA-UHFFFAOYSA-N cIMP Natural products C1=NC(C(N=CN2)=O)=C2N1C1C(O)C2OP(O)(=O)OCC2O1 DMJWGQPYNRPLGA-UHFFFAOYSA-N 0.000 description 1
230000003317 calciotropic effect Effects 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000002368 cardiac glycoside Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
239000003729 cation exchange resin Substances 0.000 description 1
229940023913 cation exchange resins Drugs 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
238000007265 chloromethylation reaction Methods 0.000 description 1
239000003245 coal Substances 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
238000012937 correction Methods 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
230000000875 corresponding effect Effects 0.000 description 1
IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
229960000258 corticotropin Drugs 0.000 description 1
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
229960000648 digitoxin Drugs 0.000 description 1
WDJUZGPOPHTGOT-XUDUSOBPSA-N digitoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O WDJUZGPOPHTGOT-XUDUSOBPSA-N 0.000 description 1
IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
208000018459 dissociative disease Diseases 0.000 description 1
238000011067 equilibration Methods 0.000 description 1
229930182833 estradiol Natural products 0.000 description 1
PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 1
229960003399 estrone Drugs 0.000 description 1
229960000304 folic acid Drugs 0.000 description 1
235000019152 folic acid Nutrition 0.000 description 1
239000011724 folic acid Substances 0.000 description 1
230000003325 follicular Effects 0.000 description 1
239000012634 fragment Substances 0.000 description 1
239000003629 gastrointestinal hormone Substances 0.000 description 1
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
229960004666 glucagon Drugs 0.000 description 1
230000014101 glucose homeostasis Effects 0.000 description 1
230000005484 gravity Effects 0.000 description 1
239000000122 growth hormone Substances 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
229910052588 hydroxylapatite Inorganic materials 0.000 description 1
230000002267 hypothalamic effect Effects 0.000 description 1
229940029329 intrinsic factor Drugs 0.000 description 1
230000029849 luteinization Effects 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
230000035800 maturation Effects 0.000 description 1
MWZPENIJLUWBSY-VIFPVBQESA-N methyl L-tyrosinate Chemical compound COC(=O)[C@@H](N)CC1=CC=C(O)C=C1 MWZPENIJLUWBSY-VIFPVBQESA-N 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
229940094443 oxytocics prostaglandins Drugs 0.000 description 1
XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
229960001723 oxytocin Drugs 0.000 description 1
238000012856 packing Methods 0.000 description 1
210000001002 parasympathetic nervous system Anatomy 0.000 description 1
239000011049 pearl Substances 0.000 description 1
XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 1
JOVOSQBPPZZESK-UHFFFAOYSA-N phenylhydrazine hydrochloride Chemical class Cl.NNC1=CC=CC=C1 JOVOSQBPPZZESK-UHFFFAOYSA-N 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
210000002381 plasma Anatomy 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
229920003053 polystyrene-divinylbenzene Polymers 0.000 description 1
229920001021 polysulfide Polymers 0.000 description 1
239000005077 polysulfide Substances 0.000 description 1
150000008117 polysulfides Polymers 0.000 description 1
239000011148 porous material Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
229940097325 prolactin Drugs 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000002787 reinforcement Effects 0.000 description 1
239000003488 releasing hormone Substances 0.000 description 1
230000003252 repetitive effect Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
230000033764 rhythmic process Effects 0.000 description 1
OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
229960000553 somatostatin Drugs 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
229960003604 testosterone Drugs 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
210000001685 thyroid gland Anatomy 0.000 description 1
239000005495 thyroid hormone Substances 0.000 description 1
229940036555 thyroid hormone Drugs 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000002792 vascular Effects 0.000 description 1
231100000925 very toxic Toxicity 0.000 description 1
238000005406 washing Methods 0.000 description 1
238000004804 winding Methods 0.000 description 1
BLGXFZZNTVWLAY-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-SCYLSFHTSA-N 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
- G01N33/538—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody by sorbent column, particles or resin strip, i.e. sorbent materials
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5302—Apparatus specially adapted for immunological test procedures
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/807—Apparatus included in process claim, e.g. physical support structures
- Y10S436/808—Automated or kit

Landscapes

Health & Medical Sciences (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Chemical & Material Sciences (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Cell Biology (AREA)
Food Science & Technology (AREA)
Medicinal Chemistry (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Microbiology (AREA)
General Health & Medical Sciences (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Automatic Analysis And Handling Materials Therefor (AREA)
Investigating Or Analysing Biological Materials (AREA)
Sampling And Sample Adjustment (AREA)

CH313277A 1976-03-12 1977-03-11 CH618516A5 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US05/666,302 US4022577A (en)	1976-03-12	1976-03-12	Automated radioimmunoassay
US05/730,630 US4104026A (en)	1976-03-12	1976-10-07	Immunoassay separation technique

Publications (1)

Publication Number	Publication Date
CH618516A5 true CH618516A5 (no)	1980-07-31

Family

ID=27099430

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CH313277A CH618516A5 (no)	1976-03-12	1977-03-11

Country Status (13)

Country	Link
US (1)	US4104026A (no)
JP (2)	JPS52161693U (no)
AU (1)	AU514237B2 (no)
BE (1)	BE852344A (no)
CA (1)	CA1083958A (no)
CH (1)	CH618516A5 (no)
DD (1)	DD130807A5 (no)
FR (1)	FR2344020A1 (no)
GB (1)	GB1574642A (no)
IL (1)	IL51636A (no)
IT (1)	IT1116804B (no)
NL (1)	NL7702530A (no)
SE (1)	SE7702800L (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4410634A (en) *	1979-10-26	1983-10-18	Dynasciences Corporation	Method of passively adsorbing immuno-reactive haptens to solid phases
JPS57131062A (en) *	1981-02-05	1982-08-13	Amano Pharmaceut Co Ltd	Quantitative determination of antigen using enzyme- labelled antigen and second antibody insolubilizing carrier
DE3122019C2 (de) *	1981-06-03	1983-11-10	Boehringer Mannheim Gmbh, 6800 Mannheim	Verfahren und Vorrichtung zur Durchführung eines automatisierten kontinuierlichen Enzymimmunotestes
EP0073593A1 (en) *	1981-09-01	1983-03-09	E.I. Du Pont De Nemours And Company	Size-exclusion heterogeneous immunoassay
JPS58154662A (ja) *	1982-03-10	1983-09-14	Hitachi Ltd	前処理機能を備えた自動分析装置
US4618485A (en) *	1982-03-12	1986-10-21	International Immunoassay Laboratories, Inc.	Kinetic radioimmunoassay test method and device
US4551298A (en) *	1982-05-26	1985-11-05	Westinghouse Electric Corp.	Radiation monitoring apparatus
US4539292A (en) *	1982-12-29	1985-09-03	Reid Michael J	Immunoassay technique for specific immunoglobulin E
US4871683A (en) *	1985-04-18	1989-10-03	Beckman Instruments, Inc.	Apparatus and method using a new reaction capsule
US5866322A (en) *	1988-01-29	1999-02-02	Abbott Laboratories	Method for performing Rubella assay
US5459078A (en) *	1988-01-29	1995-10-17	Abbott Laboratories	Methods and reagents for performing ion-capture digoxin assays
US5459080A (en) *	1988-01-29	1995-10-17	Abbott Laboratories	Ion-capture assays using a specific binding member conjugated to carboxymethylamylose
US5089424A (en) *	1988-06-14	1992-02-18	Abbott Laboratories	Method and apparatus for heterogeneous chemiluminescence assay
SE9101413L (sv) *	1991-05-10	1992-11-11	Excorim Ab	System foer behandling av en vaetska i en behandlingsanordning samt anvaendningen av detta system foer behandling av en biologisk vaetska
US5564104A (en) *	1993-06-08	1996-10-08	Cortex Biochem, Inc.	Methods of removing radioactively labled biological molecules from liquid radioactive waste
US6103127A (en)	1993-06-08	2000-08-15	Cortex Biochem, Inc.	Methods for removing hazardous organic molecules from liquid waste
US6271044B1 (en)	1998-05-06	2001-08-07	University Of Pittsburgh Of The Commonwealth System Of Higher Education	Method and kit for detecting an analyte
JP2002524723A (ja) *	1998-09-04	2002-08-06	ユニバーシティ・オブ・ユタ・リサーチ・ファウンデーション	パラクリンの尿細管レニン−アンジオテンシン系に基づく薬物スクリーニングおよび診断
US6420275B1 (en)	1999-08-30	2002-07-16	Micron Technology, Inc.	System and method for analyzing a semiconductor surface
EP1308709B1 (en) *	2001-11-01	2006-08-16	Micromass UK Limited	Sample introduction system
US7655187B2 (en) *	2005-03-11	2010-02-02	Waters Technologies Corporation	Systems for isolating toxins and collecting eluates for testing for toxins and methods using the same
US11959189B2 (en)	2019-04-11	2024-04-16	Globalwafers Co., Ltd.	Process for preparing ingot having reduced distortion at late body length
WO2020214531A1 (en)	2019-04-18	2020-10-22	Globalwafers Co., Ltd.	Methods for growing a single crystal silicon ingot using continuous czochralski method
US11111597B2 (en)	2019-09-13	2021-09-07	Globalwafers Co., Ltd.	Methods for growing a nitrogen doped single crystal silicon ingot using continuous Czochralski method
US11111596B2 (en)	2019-09-13	2021-09-07	Globalwafers Co., Ltd.	Single crystal silicon ingot having axial uniformity

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2797149A (en) *	1953-01-08	1957-06-25	Technicon International Ltd	Methods of and apparatus for analyzing liquids containing crystalloid and non-crystalloid constituents
US3690833A (en) *	1970-05-04	1972-09-12	Damon Corp	Automated fluids analyzer having selectively interrupted flow
GB1420916A (en) *	1971-09-08	1976-01-14	Bagshawe K D	Performance of chemical or biological reactions
US3843326A (en) *	1972-06-07	1974-10-22	Technicon Instr	Method and apparatus for successive sample analysis without inter-sample contamination
US3896217A (en) *	1973-03-19	1975-07-22	Summa Corp	Method and apparatus for radioimmunoassay with regeneration of immunoadsorbent
US4009005A (en) *	1973-03-19	1977-02-22	Becton, Dickinson And Company	Apparatus for radioimmunoassay with regeneration of immunadsorbent

1976
- 1976-10-07 US US05/730,630 patent/US4104026A/en not_active Expired - Lifetime
1977
- 1977-03-07 CA CA273,303A patent/CA1083958A/en not_active Expired
- 1977-03-09 NL NL7702530A patent/NL7702530A/xx not_active Application Discontinuation
- 1977-03-09 AU AU23047/77A patent/AU514237B2/en not_active Expired
- 1977-03-09 IL IL51636A patent/IL51636A/xx unknown
- 1977-03-10 IT IT48420/77A patent/IT1116804B/it active
- 1977-03-10 BE BE175696A patent/BE852344A/xx not_active IP Right Cessation
- 1977-03-11 FR FR7707318A patent/FR2344020A1/fr active Granted
- 1977-03-11 GB GB10475/77A patent/GB1574642A/en not_active Expired
- 1977-03-11 CH CH313277A patent/CH618516A5/fr not_active IP Right Cessation
- 1977-03-11 SE SE7702800A patent/SE7702800L/xx not_active Application Discontinuation
- 1977-03-11 DD DD7700197815A patent/DD130807A5/xx unknown
- 1977-03-12 JP JP1977030308U patent/JPS52161693U/ja active Pending
- 1977-03-12 JP JP2754177A patent/JPS5310495A/ja active Pending

Also Published As

Publication number	Publication date
FR2344020B1 (no)	1981-02-27
AU2304777A (en)	1978-09-14
NL7702530A (nl)	1977-09-14
JPS5310495A (en)	1978-01-30
FR2344020A1 (fr)	1977-10-07
AU514237B2 (en)	1981-01-29
IL51636A0 (en)	1977-05-31
BE852344A (fr)	1977-09-12
IT1116804B (it)	1986-02-10
US4104026A (en)	1978-08-01
DD130807A5 (de)	1978-05-03
GB1574642A (en)	1980-09-10
IL51636A (en)	1981-03-31
CA1083958A (en)	1980-08-19
JPS52161693U (no)	1977-12-07
SE7702800L (sv)	1977-09-13

Publication	Publication Date	Title
CH618516A5 (no)	1980-07-31
US3953172A (en)	1976-04-27	Method and apparatus for assaying liquid materials
US4022577A (en)	1977-05-10	Automated radioimmunoassay
US4128628A (en)	1978-12-05	Automated immunoassay
JP3149947B2 (ja)	2001-03-26	流量免疫センサ方法と装置
US4837159A (en)	1989-06-06	Method and apparatus for effecting immunological analysis
US4244694A (en)	1981-01-13	Reactor/separator device for use in automated solid phase immunoassay
EP0089346B1 (en)	1987-01-21	Automated immunoassay system
JPH06500853A (ja)	1994-01-27	固相免疫検定のための使い捨て反応容器および免疫反応により検出可能な成分の測定方法
SE450296B (sv)	1987-06-15	Forfarande for direkt bestemning av fri obunden analyt
Braithwaite	1987	Emergency analysis of paraquat in biological fluids
US3954411A (en)	1976-05-04	Preparation of reagents on-line in automated sample analysis
US4166844A (en)	1979-09-04	Solid phase separation technique for use in radioimmunoassays
EP0007229B1 (en)	1984-06-27	Assay invoving labelled substances employing a re-usable immobilised binder
JPS61193073A (ja)	1986-08-27	免疫学的分析方法およびその装置
CA1088421A (en)	1980-10-28	Automated immunoassay
JPH0577981B2 (no)	1993-10-27
Munson	1986	Analytical techniques in dissolution testing and bioavailability studies
JPH0619358B2 (ja)	1994-03-16	免疫学的自動分析方法
RU2090892C1 (ru)	1997-09-20	Способ определения биологически активных веществ
JPS61118662A (ja)	1986-06-05	免疫学的自動分析方法
JPS61117455A (ja)	1986-06-04	免疫学的自動分析方法
JP6476705B2 (ja)	2019-03-06	抗原検出のための前処理方法
JPH02245665A (ja)	1990-10-01	自動生化学分析装置
FR2634891A1 (fr)	1990-02-02	Procede et dispositif pour la determination qualitative et/ou quantitative d'un ligand dans un fluide

Legal Events

Date	Code	Title	Description
1993-11-30	PL	Patent ceased
2024-10-31	PL	Patent ceased